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High diagnostic performance of CT scan for analgesic nephropathy in
patients with incipient to severe renal failure. Recently, well performing
diagnostic criteria for analgesic nephropathy in end-stage renal failure
(ESRF) patients were defined by the demonstration of a bilateral decrease
in renal volume combined with either bumpy contours or papillary
calcifications. In this study, the diagnostic value of computed tomography
(CT) scan was compared to the previously used renal imaging techniques
(sonography and conventional tomography). In a first study, a cohort of 40
analgesic abusers (defined as daily use of analgesic mixtures during at least
5 years) and 40 controls, all ESRF patients without a clear renal diagnosis,
were investigated with sonography, tomography and CT scan without
injection of iodinated contrast material, to search for the imaging signs of
analgesic nephropathy. Using CT scan, sonography and tomography, renal
size could be evaluated with comparable results while CT scan was
superior in the detection of papillary caleifications (sensitivity 87%,
specificity 97%). In a second controlled study of 53 analgesic abusers with
a serum creatinine between 1.5 to 4 mg/dl in the absence of a clear renal
diagnosis, a CT scan was performed and scored for the presence of
decreased renal volume, bumpy contours and papillary calcifications. It
was found that the renal image of analgesic nephropathy on CT scan in an
early stage of renal failure is comparable with the observations made in
ESRF patients. Particularly the demonstration of papillary calcifications
showed a high sensitivity of 92% with a specificity of 100% for the early
diagnosis of analgesic nephropathy.
Analgesic nephropathy is underestimated in several countries,
mainly due to the lack of well defined criteria for diagnosing this
disease. This observation formed the basis of a study starting in
Belgium in 1988 which aimed to establish diagnostic criteria for
analgesic nephropathy in patients with ESRF. In a cohort of 60
analgesic abusers and 188 controls, all starting renal replacement
therapy, a large number of clinical, laboratory and radiological
signs reported to be associated with analgesic nephropathy were
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evaluated. Renal imaging investigations (sonography and tomog-
raphy) demonstrating a decrease in length of both kidneys com-
bined with either bumpy contours or signs of renal papillary
necrosis showed a high sensitivity and specificity for diagnosing
the disease. Other signs frequently mentioned, such as hyperten-
sion, anaemia, sterile pyuria and bacteriuria, showed insufficient
sensitivity and/or specificity [11.
During the Analgesic Nephropathy Network Europe (ANNE)
study, the criteria selected in Belgium, were evaluated in 23 renal
units from 14 European countries and Brazil. Results, based on 82
analgesic abusers and 495 controls, all dialysis patients starting renal
replacement therapy with an unclear renal diagnosis, corroborated
the diagnostic performance of the renal imaging criteria [21.
Out of these studies it was learned, however, that the results of
sonography were strongly operator related and that the poor
spatial resolution of sonography limits its usefulness in the
assessment of papillary necrosis, as was also mentioned by Dav-
idson and Hartman [31. Additionally, the quality of conventional
tomography showed a high technical variability, and the use of the
latter technique became more and more questionable due to the
high dose of ionizing radiation administered to the patients. In
contrast, preliminary observations with CT scan showed that this
renal imaging technique has a high sensitivity particularly for the
detection of papillary calcifications.
CT demonstration of papillary calcifications in analgesic ne-
phropathy patients was reported in several publications [3—6J. The
diagnostic performance of this renal imaging technique, however,
was never investigated nor validated in a representative sample of
analgesic abusers and controls. Furthermore, it is unknown
whether the renal imaging criteria, developed for ESRF patients,
are also useful in patients presenting at the outpatient clinic with
incipient to moderate renal failure. Particularly, the question
arises as to whether renal papillary necrosis can also be demon-
strated at an early stage of renal failure.
This paper reports on a study of the value of the CT scan for
diagnosing analgesic nephropathy in ESRF as well as in patients
with incipient to moderate renal failure.
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Fig. 1. Description of the renal imaging criteria of analgesic nephropathy as observed on CT scan including a decreased renal volume, bumpy Contours and
papillary calcifications. Renal size was measured by the sum of both sides of the rectangle enclosing the kidney at the level of the renal vessels.
Indentations were counted at the level where most indentations were present. Triangular, ringlike or polygonic calcifications on the papillary line were
considered as signs of renal papillary necrosis.
Methods
Patients with ESRF
All ESRF patients from six Belgian dialysis units, either starting
renal replacement therapy or presenting at the outpatient clinic
with a measured creatinine clearance below 20 mI/mm, were
considered for enrollment in the study. Enrollment was limited to
either patients admitting the abuse of analgesics (abusers) or
patients who had never consumed analgesics regularly (controls).
In both groups only patients without a clear renal diagnosis were
included. Patients with a clear renal diagnosis (histologically
proven glomerulonephritis, polycystic disease, hereditary familial
nephropathy, congenital renal hypoplasia, diabetic nephropathy
and other systemic diseases) were excluded from investigation.
All patients included underwent a short interview in order to
document a possible history of abuse. Analgesic abuse was
investigated using three different techniques identical to the
methodology used in the preceeding diagnostic criteria studies [1,
21. First, there was a general question concerning the medication
taken during the last month. Second, the regular use of medica-
tion for relief of complaints such as headache and joint pain was
investigated. Third, the consumption of analgesics was tested
using a picture book, containing photographs of the twelve
Table 1. Renal diagnoses in controls (N = 40)
EDTA code Description %
0 Unknown etiology 17.5
10 Glomerulonephritis (no biopsy) 17.5
20—25 Pyelonephritis 32.5
70—72 Vascular disease 25.0
99 Other 7.5
best-selling analgesics in Belgium. It was used to test the patient's
knowledge of the product, if he had it at home and how frequently
he was using it. Analgesic abuse was defined as a daily use of
analgesic mixtures for at least five years. Analgesic mixtures were
defined as products containing two analgesic components com-
bined with potentially addictive substances (caffeine, codeine).
A sonography, tomography and CT scan were performed in all
patients included. To increase the quality of the renal imaging
investigations, local radiologists and sonographists were contacted
prior to the start of the study. Per center all investigations were
performed by the same experienced radiologist. Results of the
renal imaging investigations were noted on appropriate forms by
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N=40 abusers
Fig. 2. CT scan compared to sonography and
tomography in their detection of a decreased renal
volume (N = 40 abusers with ESRF).
the local radiologist. For sonography and tomography, decrease in
length, bumpy contours and papillary calcifications were defined
as described previously [1].
CT scans were performed without injection of iodinated con-
trast material. Contiguous slices from the upper to the lower pole
of both kidneys were made. Use of slice thickness of 10 mm, 120
Ky and a scan time of less than three seconds were recommended.
A field of view between 30 to 38 was used with a scale bar added.
On the CT scan, the renal volume was examined by measuring
both sides of the rectangle enclosing the kidney at the level of the
renal vessels. To evaluate the renal contours, irregularities were
evaluated at the level where most indentations could be observed
and were quoted as 0, 1 to 2, 3 to 5, or more than 5 indentations.
If at least 3 indentations were observed, the contour was consid-
ered to be "bumpy." Calcifications were localized as cortical,
papillar or central. Triangular, ringlike or polygonic calcifications
on the papillary line [5] were considered as signs of renal papillary
necrosis (Fig. 1).
Normal values for the renal volume evaluation using CT scan
were established investigating 183 patients without renal disease,
stratified according different age and sex categories. The sum of
both sides of the rectangle enclosing the kidney at the level of the
vessels (Fig. 1) showed bilaterally comparable results with mean
values of 112 and 114 mm for the left and the right kidney,
respectively. Logistic regression, including sex, age, body length
and weight in the analysis, showed that sex has to be taken into
account for evaluating the renal volume as measured on CT scan.
The renal volume was considered as decreased if the sum of both
sides of the rectangle (A + B on Fig. 1) was less than the 5th
percentile rank of the normal population. Cut-off values for males
and females were respectively 103 and 96 mm.
Additionally, the diagnostic value of CT scan in the case of
analgesic nephropathy in ESRF patients was validated using all
CT scan documents (N = 67) performed within the framework of
the ANNE study in seven other renal units [2]. The renal imaging
criteria were validated by a radiologist (ADS) who was not
involved in the process of data collection, and without knowledge
of a possible history of abuse. His validation consisted of a blind
re-examination of the CT scans, accepting or rejecting the diag-
nosis of analgesic nephropathy based on the observation of a
Fig. 3. CT scan compared to sonography and tomography in their detection
of papillaty calcifications (N = 40 abusers with ESRF).
decrease in renal volume plus either bumpy contours or papillary
calcifications. Afterwards, these results were compared with the
possible history of analgesic abuse.
Patients with incipient-moderate renal failure
In six Belgian renal units and seven ANNE centers, patients
presenting at the outpatient clinic with a clear history of analgesic
abuse (daily use of analgesic mixtures during at least 5 years), with
a serum creatinine between 1.5 to 4 mg/dl and in the absence of a
clear renal disease were selected. All patients meeting these
conditions in one of the collaborating centers had to be included
in the study.
Data documenting the chronic character of the renal failure (3
measurements of serum creatinine over a one year period) and
the abuse of analgesics (duration and amount of abuse, kinds of
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Fig. 4. Performance of the renal imaging criteria
using CT scan in patients with ESRF.
Combination can be defined as a decreased
renal volume combined with either bumpy
contours or papillary calcifications.
products used) were noted. All selected patients underwent a
routinely performed CT scan without contrast.
Information sheets and CT scans were sent to the coordinating
center where CT scans were reviewed, evaluating the renal
volume and the contours, and searching for possible calcifications
on the papillary line. Identical criteria as described for ESRF
patients were used to quote decreased renal volume, bumpy
contours and papillary calcifications.
Additionally, all available CT scans without contrast, performed
in the coordinating center in patients without a history of abuse
showing a serum creatinine between 1.5 to 4 mgldl in the absence
of a clear renal diagnosis, were collected. These CT scans were
also reviewed for the presence or absence of a decreased renal
volume, bumpy contours and papillary calcifications. In the coor-
dinating center, analgesic consumption was routinely investigated
in all new patients. Patients were selected as controls if no
indication could be found suggesting a regular analgesic consump-
tion.
Statistical methods
Data analysis was performed using the BMDP statistical pack-
age for medical sciences [7]. The group of patients with a history
of analgesic abuse was compared to the group of patients without
analgesic abuse regarding the renal imaging criteria of analgesic
nephropathy. For all renal imaging signs with a statistical differ-
ence (P < 0.05) between both groups, the sensitivity and speci-
ficity was computed. Additionally, the predictive values were
calculated using the Bayes' theorem [8]. Probability graphs were
constructed depicting diagnostic values for pre-test probabilities
ranging from 0 to 50%.
Results
Patients with ESRF
Results are based on 80 new ESRF patients without a clear
renal diagnosis consisting of 40 abusers (daily use of analgesic
mixtures for minimum 5 years) and 40 controls (no history of
abuse). Mean age was respectively 67 ( 7) and 62 (± 15) years.
Male/female ratio was 1/9 for abusers and 5/5 for controls.
Distribution of the renal diagnosis in controls is shown in Table 1.
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Fig. 5. Positive and negative predictive values for diagnosing analgesic
nephropathy using CT scan in patients with ESRF. Probability graph
depicting the diagnostic value of detecting papillary calcifications (given a
sensitivity of 87%, a specificity of 97% and a prevalence of analgesic abuse
of 50%). Curved lines indicate the predictive values (positive and nega-
tive) of diagnosing AN for different prevalences of analgesic abuse
(pre-test probability) [81.
In abusers, the regular intake of analgesic mixtures, all containing
two analgesic components plus caffeine/codeine, varied from 5 to
50 years (mean 21.5 10.2) with a daily consumption ranging
from 1 to 10 units (mean 3.5 1.7; 1 unit = 1 tablet or 1 dose of
powder).
Using CT scan, the mean renal sizes in abusers were 79 (± 13)
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Fig. 6. Evaluation of the value of CT scan for
diagnosing analgesic nephropathy in ESPY
patients, performing a blind re-examination of 67
CT scans. Positive diagnosis of analgesic
nephropathy was based on the observation of a
decrease in renal volume combined with either
bumpy contours or papillary calcifications.
and 91 (± 15) mm for the left and right kidneys, respectively.
Comparing CT scan to sonography and conventional tomography
for evaluating the renal volume, comparable results were obtained
on the left side (Fig. 2). The right kidney was found to be more
susceptible to inclinations on the length axis, resulting in a false
increase of the antero-posterior measurement of the right kidney
(size A in Fig. 1) in one fourth of the abusers. Bumpy contours
were observed in 50% ofabusers using CT scan compared to 30%
using sonography and 30% using tomography. The CT scan
clearly was superior in the detection of papillary calcifications
demonstrated bilaterally in all cases except two (Fig. 3).
Using CT scan, a sensitivity of 90% and a specificity of 90% was
obtained for a combination of the renal imaging criteria (bilateral
decrease in renal volume and either bumpy contours or papillary
calcifications). Limiting the criteria to the detection of papillary
calcifications, sensitivity and specificity remained respectively 87%
and 97% (Fig. 4).
In Figure 5 the positive and negative predictive values of the CT
scan for detecting papillary calcifications are presented. A positive
predictive value of up to 97% could be reached, given a preva-
lence of analgesic abuse of 50% in this particular study. However,
even with a prevalence of 10%, a positive predictive value of 80%
can be obtained with a negative predictive value remaining above
the 90% level.
For validation of the renal imaging criteria, 67 CT scans
performed in other renal units were re-examined by our radiolo-
gist (ADS) who was not involved in the process of data collection.
The diagnosis of analgesic nephropathy was accepted or rejected
based on the observation on a CT scan of a decrease in renal
volume combined with either bumpy contours or papillary calci-
fications. As shown in Figure 6, this blind re-examination resulted
in a comparable number of patients in whom the diagnosis of
analgesic nephropathy was accepted or rejected, even in the
absence of any knowledge of their history of analgesic abuse. An
overall accordance of 94% was obtained between the original
examination and the blind re-examination.
Patients with incipient to moderate renal failure
Results are based on 53 abusers (9 males, 44 females) with a
mean age of 63 years (range 37 to 80) and with a mean serum
creatinine of 2.4 mg/dl (range 1.5 to 3.9). In all these patients a
daily use of analgesic mixtures during a period ranging from 6 to
42 years was documented. Results were compared to CT scans of
30 controls without a history of analgesic abuse and with an
unclear renal diagnosis: unknown etiology (N = 11), glomerulo-
nephritis without biopsy (N = 4), pyclo/interstitial nephritis (N =
4), renal vascular disease (N = 8) and other renal diseases (N =
3). Mean age in controls was 58 years (range 36 to 80). They
presented with a mean serum creatinine of 2.5 mg/dl (range 1.5 to
4).
As shown in Figure 7, the CT scan appearance of analgesic
nephropathy in an early stage of renal failure is strikingly compa-
rable with the observations made in ESRF patients. Indeed, even
in abusers with a serum creatinine below 2 mg/dl, a decreasing
renal volume, irregular contours and signs of papillary necrosis
were clearly demonstrated. These criteria could be observed
regardless the technical specifications of the scanner used (Fig. 8
CT scan from the Republic of Slovakia, Italy and Belgium). Renal
size measurements in abusers showed a mean of 88mm (t 13) for
the left kidney and 93 mm (± 18) for the right kidney, while the
mean renal size in controls was 105 (t 16) and 106 (± 18) mm,
respectively. Particularly the demonstration of calcifications on
the papillary line showed a high sensitivity of 92% with a
specificity of 100% for the early diagnosis of analgesic nephrop-
athy (Fig. 8). Comparing this diagnostic performance with results
obtained in ESRF patients, sensitivity and specificity even slightly
improved concerning the demonstration of bumpy contours and
papillary calcifications. The finding of a decreased renal volume
showed only a limited sensitivity while its specificity largely
increased compared to ESRF.
In incipient to moderate renal failure the bilateral appearance
of the lesions also has to be emphasized. Although some abusers
showed a right kidney slightly larger in size compared to the left
(sec also ESRF patients), all patients showed a bilateral incipient
shrinkage (decreased renal size and/or minimal 1 to more than 5
indentations). Papillary calcifications were observed bilaterally
except in 5 out of 53 patients.
Discussion
This paper deals with the performance of renal imaging criteria
for diagnosing analgesic nephropathy using a CT scan without
contrast. The criteria studied (that is, a bilateral decrease in renal
volume combined with bumpy contours and/or papillary calcifica-
tions) were selected during a precceding study performed in
Belgium, which investigated all new ESRF patients with sonogra-
phy and tomography [11, and was corroborated in other European
countries during the ANNE study [2]. In this final study, we were
able to demonstrate that the use of a routinely performed CT scan
further augmented the sensitivity and specificity of the renal
imaging criteria, particularly for the detection of papillary calci-
fications. In addition, it was found that the diagnostic criteria
studied are equally useful in patients with incipient to moderate
renal failure.
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Fig. 7. CT scan appearance of analgesic nephropathy in an early stage of renal failure.
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Fig. 8. Performance of the renal imaging criteria
using CT scan in patients with incipient-moderate
renal failure (Se-., = 1.5 to 4 mg/dl or 170 to 450
mmol/liter). Combination 1 can be defined as a
decreased renal volume combined with either
bumpy contours or papillary calcifications.
Combination 2 can be defined as papillary
calcifications combined with either bumpy
contours or decreased renal volume.
Renal papillary necrosis is also described in diabetic nephrop-
athy, obstructive uropathy and sickle-cell anemia [9]. This impor-
tant differential diagnostic issue was thoroughly investigated in the
two preceeding studies in which respectively 188 and 495 controls
with ESRF were investigated. During the study selecting the
criteria in Belgium, papillary calcifications in association with the
other renal imaging features of analgesic nephropathy were only
observed in two out of 33 controls with diabetic nephropathy and
in one out of four controls with obstructive uropathy [1]. During
the ANNE study only 3 out of 94 controls with diabetic nephrop-
athy and 3 out of 25 controls with obstructive uropathy showed
positive renal imaging criteria of analgesic nephropathy [2]. In
contrast with analgesic nephropathy, the unilaterality of the
lesions in a large part of cases with pyelonephritis was emphasized
[10].
In patients with incipient to moderate renal failure, radiologi-
cally detectable kidney calcifications were also described in pri-
mary hyperparathyroidism and renal tubular acidosis. In these
specific clinical entities, however, the accompanying kidney
shrinkage was not mentioned and calcifications were not arranged
on the papillary line, but showed a more diffuse distribution
among the kidney tissue [31
For the diagnosis of analgesic nephropathy, the detection of
papillary calcitications has a particularly high sensitivity and
specificity in ESRF patients as well as in patients with incipient to
moderate renal failure. In clinical practice, however, an accom-
panying shrinkage of both kidneys and the bilateral occurrence of
the lesions has to be observed for diagnosing analgesic nephrop-
athy. A decreased renal volume will he based on the renal size
measurement performed at the left side. In 22% of all abusers
investigated renal size of the right kidney considerably exceeded
that of the left kidney because of an increase in the anterio-
posterior measurement of the right kidney (size A in Fig. 1). This
may be attributed to an increased pressure of the liver causing an
inclination on the length axis of the right kidney.
In our studies, patients were selected as "case" or "control"
based on their history of abuse or non-abuse. Although several
authors mentioned the difficulties in detecting a history of anal-
gesic abuse [11, 121, the use of different interview techniques
(noted in Methods), complemented by insights from the respon-
sible nephrologist concerning the analgesic consumption of his
patient, clearly improves the bias on the history of analgesic
consumption.
Based on our previous observations [13], a daily consumption of
analgesic mixtures for minimum five years was used as the
inclusion criterium for analgesic abuse. This definition was eval-
uated during the analysis of the ANNE data [2]. None of the
subjects with a daily use of analgesic mixtures for less than five
years (N = 16), nor those with a weekly but not a daily analgesic
consumption of mixtures for more than five years (N = 19) met
the renal imaging criteria of analgesic nephropathy. Moreover,
the diagnostic criteria studies, investigating a total cohort of 226
abusers, clearly revealed that analgesic nephropathy is associated
with the abuse of different kinds of analgesic mixtures, all
containing two analgesic components combined with potentially
addictive substances like caffeine or codeine [13]. The nephrotox-
icity of the following combinations could be documented: salicylic
acid/phenacetin, phenacetin/pyrazolones, salicylic acid/paraceta-
mol, salicylic acid/pyrazolones, paracetamol/pyrazolones and a
combination of two pyrazolones.
Several authors described the characteristic appearance of
analgesic nephropathy using CT scan investigations [5, 31. More-
over, Weber et al [141 as well as Segasothy et a! [6] reported on a
comparative study for diagnosing analgesic nephropathy using CT
scan and respectively conventional radiology plus sonography or
sonography alone, searching for the presence of papillary calcifi-
cations. Although both studies describe the characteristics of
analgesic nephropathy using different renal imaging techniques,
the diagnostic performance and validation was not studied. More-
over, definition of analgesic abuse varied considerably in these
studies, also taking into account the use of NSAID's and a less
than daily consumption of analgesics.
Until now, the diagnosis of analgesic nephropathy was difficult
to obtain because the disease was associated with a large number
of mainly aspecific clinical symptoms. Moreover, renal papillary
necrosis, considered as the hallmark of analgesic nephropathy,
Elseviers et al: CT scan for diagnosing analgesic nephropathy 1323
could only be directly demonstrated by autopsy, after nephrec-
tomy or in the exceptional case of a patient eliminating a papilla.
In a large number of cases, the diagnosis was mainly based on a
documented history of abuse after a process of exclusion of other
causes of renal failure.
Particularly because in recent years a considerable number of
epidemiological observations pointed to an underestimation of
this renal disease [15, 16], the need for diagnostic criteria with a
well defined performance became obvious. These criteria will also
allow prevalence measurements to start in countries where this
has never been performed before. Moreover, a clear and uniform
diagnosis of analgesic nephropathy will be helpful for collecting
the epidemiological data needed to identify the nephrotoxic
culprits among the analgesics currently marketed. Since phenac-
etin has disappeared from the market but analgesic nephropathy
still occurs frequently, this discussion has again gained importance
[17, 181.
Based on the results of this study and the previous diagnostic
criteria studies, we recommend a routinely performed CT scan in
all patients with unclear renal diagnosis, in order to consider
analgesic nephropathy as the possible cause of renal failure, even
in the absence of reliable information on previous analgesic
consumption.
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